15d
Gerresheimer AG (GRRMY) reports robust Q4 growth driven by biologics, despite challenges in full-year performance and market dynamics.
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback